ICLR:NSD-ICON PLC (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 203.9

Change

-8.37 (-3.94)%

Market Cap

USD 18.82B

Volume

1.80M

Analyst Target

USD 199.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+3.71 (+0.87%)

USD 34.17B
ILMN Illumina Inc

-1.45 (-0.98%)

USD 23.86B
NTRA Natera Inc

+25.85 (+19.13%)

USD 15.36B
EXAS EXACT Sciences Corporation

+0.57 (+1.14%)

USD 13.02B
MEDP Medpace Holdings Inc

+1.13 (+0.31%)

USD 9.93B
RDNT RadNet Inc

-1.03 (-1.23%)

USD 5.00B
SHC Sotera Health Co

-0.22 (-1.42%)

USD 4.49B
GH Guardant Health Inc

+1.88 (+6.32%)

USD 3.53B
NEOG Neogen Corporation

-0.16 (-1.04%)

USD 3.13B
TWST Twist Bioscience Corp

-2.77 (-6.12%)

USD 2.66B

ETFs Containing ICLR

IRESF iShares Public Limited Co.. 16.68 % 0.00 %

-0.10 (-0.80%)

N/A
EIRL iShares MSCI Ireland ETF 16.64 % 0.47 %

-1.39 (-0.80%)

USD 0.08B
PCIG Litman Gregory Funds Trus.. 10.24 % 0.00 %

-0.08 (-0.80%)

USD 0.03B
XGES:LSE Xtrackers MSCI Genomic He.. 4.62 % 0.00 %

+0.09 (+-0.80%)

N/A
BBH VanEck Biotech ETF 4.59 % 0.35 %

+0.36 (+-0.80%)

USD 0.43B
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.57 % 0.00 %

+0.16 (+-0.80%)

N/A
W311:XETRA HAN-GINS Indxx Healthcare.. 4.30 % 0.00 %

+0.01 (+-0.80%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 4.30 % 0.00 %

+0.02 (+-0.80%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 4.30 % 0.00 %

-0.01 (-0.80%)

N/A
QQQN VictoryShares Nasdaq Next.. 2.26 % 0.00 %

N/A

USD 0.02B
QQJE:CA Invesco ESG NASDAQ Next G.. 1.97 % 0.00 %

-0.13 (-0.80%)

CAD 0.99M
EQQJ:LSE Invesco NASDAQ Next Gener.. 1.83 % 0.00 %

+0.28 (+-0.80%)

N/A
EQQJ:SW Invesco NASDAQ Next Gener.. 1.78 % 0.00 %

N/A

N/A
JNDQ:AU BETAJNDQ ETF UNITS 1.77 % 0.00 %

-0.09 (-0.80%)

N/A
EQQJ:XETRA Invesco NASDAQ Next Gener.. 1.54 % 0.00 %

+0.25 (+-0.80%)

USD 0.05B
GNRX 0.00 % 0.55 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
IREMF 0.00 % 0.00 %

N/A

N/A
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

+0.04 (+-0.80%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -27.97% 40% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.97% 40% F 27% F
Trailing 12 Months  
Capital Gain -24.14% 40% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.14% 40% F 26% F
Trailing 5 Years  
Capital Gain 31.90% 75% C 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.90% 75% C 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 14.90% 62% D 68% D+
Dividend Return 14.90% 62% D 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.36% 92% A 64% D
Risk Adjusted Return 52.55% 92% A 80% B-
Market Capitalization 18.82B 95% A 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.